ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2021 Congress

July 17-21, 2021. Philadelphia, PA.

View by Title View by Number View Themes
Jump to:  View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: OC 56.4

    F8 Genetic Variants Associated with Inhibitor Development in a Multiethnic Population of Non-severe Hemophilia A

    M.Y. Lim1,1, K. Lee2, N.S Key2

  • Abstract Number: PB1124

    Factor VIII and Prothrombin Time during Induction Therapy Correlate with Response to Treatment in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients

    J. Vieira1, A. Vagos Mata1, I. Paulos Mesquita1, S. Durão1, H. Martins1, A. Rodrigues1, A. Garção1, Á. Beleza1, J. Raposo1, G. Esteves1

  • Abstract Number: OC 55.3

    Factor VIII Inhibitors: Effects of Mutation and FVIII Antigen Revisited

    S. Kuldanek1, D. Thornhill1, A. Tran1, N. Briones1, C. Baird1, L. Jacobson1, B. Warren1, M. Manco-Johnson1

  • Abstract Number: PB1096

    Factor VIIIc Predicts Venous Thromboembolism in Gynecological Cancer Patients

    E. Ibrahim1,2, S. O'Toole1,3,4, M. Ward4,3, F. Abu Saadeh1,2, L. Norris1,3

  • Abstract Number: PB0697

    Factor XI Deficiency in Pregnant Women: A Genotype to Phenotype Correlation and Analysis

    G. Sacchi de Camargo Correia1, S. Rajeeve2, L. Cytryn1

  • Abstract Number: PB0044

    Factor XIa Inhibitor Milvexian (BMS-986177/JNJ-70033093) Suppresses Plasma Clot Formation and Reduces Resistance to Fibrinolysis in vitro

    L.A. Holle1, J.M. Luettgen2, A.S. Wolberg1

  • Abstract Number: PB1144

    FACTOR XII 46 C/T Gene Polymorphism as a Possible Risk Factor for Late-onset Venous Thromboembolism in Patients from the North-Western Russia

    A. Chechulova1, S. Kapustin2, V. Soroka1, V. Soldatenkov2, L. Papayan2, M. Galchenko3

  • Abstract Number: OC 22.3

    Factor XIII Increases Cerebral Infarct Size by Promoting Thrombus Stabilization and Resistance to Revascularization Treatments in Ischemic Stroke

    J. Marta-Enguita1, F. Machado1, M. Navarro-Oviedo1, I. Esquisabel1, C. Roncal1,2, J.-A. Páramo1,2,3, R. Muñoz4, J. Orbe1,2

  • Abstract Number: PB0800

    Factors, Determining Thrombus Recanalization in Children with Different Blood Disorders

    P.A Zharkov1, D.A Evstratov1, K.A Voronin1, D.V Fedorova1, A.V Pshonkin1

  • Abstract Number: PB0718

    Familial Multiple Coagulation Factor Deficiencies (FMCFDs); A Rare Case of Combined Deficiency of Factor V and Factor VIII (F5F8D)

    J. Rigano1

  • Abstract Number: PB0827

    Fatigue in Chronic Immune Thrombocytopenia Patients: Validation of the Checklist Individual Strength and Comparison to Other Chronically Ill Populations

    W.E.M. van Dijk1, I.A.R. Kuijlaars1, M.H. Suijker2, K.P.M. van Galen1, R.E.G. Schutgens1

  • Abstract Number: PB0626

    Feasibility of Integrating PROBE (Patient Reported Outcomes, Burdens and Experiences) into a Clinical Care Pathway to Facilitate Transformation to a Value-based Health Care Model in Hemophilia

    S. Jackson1,2, B. Sheridan2, D. Gue3, S. Lyons3, R. Waines3, T. Ireland3, D. Pete4, A. Iorio5,4, L. Walsh4, M. Skinner6, F. Germini7,8

  • Abstract Number: PB0540

    Feasibility of Measuring through PROMIS Computer Adaptive Tests (CATs) and Short Forms (SFs) in Haemophilia – Preliminary Data

    I.A. Kuijlaars1, L. Teela2, J.J. Muis2,3, E.S. van Hoorn4, L. van Vulpen5, M. Timmer5, M. Coppens6, S.C. Gouw3,7, M. Peters3, M.J. Kruip8, M.H. Cnossen9, L. Haverman2, K. Fischer5

  • Abstract Number: OC 47.4

    Features of Aspirin-resistant Biomechanical Platelet Activation in Fibromuscular Dysplasia

    R. Bhandari1, S. Shim1, M. Godwin1, A. Aggarwal1, N. Fendrikova-Mahlay1, S. Hazen1, A.P. Owens2, A. ElBadawi3, S. Cameron1

  • Abstract Number: PB0318

    Features of the Coagulation Potential of Blood in Patients with Endometriosis

    I. Vasilenko1,2, R. Lifenko3, S. Gasparyan4, Z. Kardashova1, E. Rusanova1

  • Abstract Number: PB0145

    Fibrin Clot Characteristics and Anticoagulant Response in a SARS-CoV-2 Infected Endothelial Cell Model

    C. McCafferty1, L. Lee2, T. Cai1, S. Praporski1, V. Karlaftis1, C. Attard1, S. Van Den Helm1, N. Letunica1, J. Stolper1, D. Elliott1, K. Subbarao3,2, P. Monagle4,5,1, V. Ignjatovic1,4

  • Abstract Number: PB0139

    Fibrinogen Adsorption on Hemofilter Membranes Associates with Severe COVID-19 and Renal Replacement Therapy Circuit Failure

    D. Choi1, F. Liu2, A. Borczuk3

  • Abstract Number: PB0235

    Fibrinogen and D-dimer Are Significantly Associated with Severity of COVID-19 Disease

    M. El Horri1, S.N.E. Touati1, I. Khachaa1, A. Chikh Khelifa1, A. Berrah1, L. Benmahdi1, S.E. Belakehal1

  • Abstract Number: PB0707

    Fibrinogen Austin (Aα17Gly→Cys and Aα381Ser→Phe); Identification of a Novel Fibrinogen Mutation Causing Dysfibrinogenaemia

    J. Rigano1

  • Abstract Number: PB0400

    Fibrinogen B Arg448Lys and Factor XIII Val34Leu Polymorphisms Are Associated with Prothrombotic Fibrin Clot Properties in Patients with Acute Pulmonary Embolism

    A. Klajmon1, J. Chmiel2, M. Ząbczyk2,1, J. Natorska2,1, A. Undas2,1

  • Abstract Number: PB0735

    Fibrinogen Binding to Macrophages Attenuates Antiviral Responses to dsRNA

    D. Martinez1, M.J. Flick1, S. Antoniak1

  • Abstract Number: PB0416

    Fibrinolytic Disorders as Cause of Bleeding in Patients with an Increased Bleeding Tendency

    L. Valke1,2, D. Meijer3, L. Nieuwenhuizen2,4, B. Laros-van Gorkom1,2, N. Blijlevens1, W. Van Heerde2,5, S. Schols1,2

  • Abstract Number: OC 46.2

    Fibrinolytic Shutdown Is Associated with Death, Mild Lung Injury and a New VV ECMO Requirement after Cardiac Surgery; A Single Center Case-control Study of 742 Patients

    S. Wickers1, N. Clendenen2

  • Abstract Number: PB0521

    Final Analysis of the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with Factor (F)VIII Inhibitors

    V. Jiménez-Yuste1, F. Peyvandi2, R. Klamroth3, G. Castaman4, C. Shanmukhaiah5, S. Rangarajan6, J. García Chavez7, R. Martinez8, G. Kenet9, H. Alzahrani10, S. Robson11, C. Schmitt11, A. Kiialainen11, O. Meier11, M. Ozelo12

  • Abstract Number: PB1232

    Final Results (765 Answers) of the Brazilian National Survey in Thromboprophylaxis for Varicose Vein Surgery

    A.J. Ribeiro1, M.A. Marques2, F.L. Erzinger3, A. Ribeiro4.

  • Abstract Number: PB0522

    Final Results of ReITIrate – A Prospective Study of Rescue Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc (rFVIIIFc) in Patients who Have Failed Previous ITI Attempts

    C. Königs1, S. Meeks2, M. Löfqvist3, J. Dumont4, L. Leickt3, S. Nayak3, S. Lethagen3

  • Abstract Number: PB0945

    Finding the Balance between Bleeding Risk and Thromboembolic Risk: A Case Report

    B. Merchan Muñoz1, S. Herrero Martín1, M.I. Nuevo López1, M. Mora Argumánez1

  • Abstract Number: PB0097

    First Case of Wunderlich Syndrome under Apixaban – Case Report

    T. Quaresma1, S. Maltês2, C. Carvalho Gouveia3, D.J. Canudo4, M. Rebelo5, F. Serrazina6, M.M. Deveza1, M. Galvão1

  • Abstract Number: PB0570

    First Interim Analysis from the Observational HEM-POWR Study Evaluating Effectiveness and Safety of Real-world Treatment with Damoctocog Alfa Pegol in Previously Treated Patients with Hemophilia A

    M. Reding1, M. Teresa Alvarez Román2, M. Sanabria3, G. Castaman4, M. Janbain5, T. Matsushita6, K. Meijer7, K. Schmidt8, J. Oldenburg9

  • Abstract Number: OC 08.1

    First Interim Analysis of a 24-month French, Multicentre, Prospective, Non-interventional Study Evaluating the Real-world Usage and Effectiveness of the Extended Half-life Recombinant Factor IX Fc Fusion Protein (rFIXFc) in People with Haemophilia B (B-SURE)

    H. Chambost1, A. Rauch2, Y. Repesse3, S. Claeyssens4, S. Castet5, R. d'Oiron6, E. Santagostino7, C. Martinez8

  • Abstract Number: PB0526

    Fitusiran Population Pharmacokinetic and Pharmacodynamic (PopPK/PD) Modeling to Support Revised Dose, Dosing Regimens & Dose Mitigation Scheme

    P. Bhagunde1, S. Ge1, S. Iqbal2, B. Mei2, S. Andersson2, V. Kanamaluru1, Q. Lu1

  • Abstract Number: OC 26.3

    Five Year Data Confirms Stable FIX Expression and Sustained Reductions in Bleeding and Factor IX Use Following AMT-060 Gene Therapy in Adults with Severe or Moderate-severe Hemophilia B

    W. Miesbach1, K. Meijer2, M. Coppens3, P. Kampmann4, R. Klamroth5, R. Schutgens6, G. Castaman7, E.K Sawyer8, F.WG Leebeek9

  • Abstract Number: PB0121

    Fixed-dose 1500-unit 4F-PCC for Factor Xa inhibitor Reversal in Spontaneous or Traumatic Intracranial Hemorrhage

    S. Lujan1, C. Rodriguez1, M. Mason1, L. Anselmo1, T. Goot1, A. Burnett1

  • Abstract Number: PB0006

    Flowcytometric Assay of Platelet-derived Microparticles and the Dual Anti-platelet Therapy in Egyptian Patients with Ischemic Heart Disease, a Promising Indicator

    N. Farouqe1, M. Wahba1, A. Saad1, R. El-Gamal1, Y. Elsakhawy1, M. Farouk2

  • Abstract Number: OC 05.2

    Fluorescence Correlation Spectroscopy Provides New Insights into the Mechanism of Prothrombin Recognition by the Prothrombinase Complex

    M. Chinnaraj1, N. Pozzi1, E. Di Cera1

  • Abstract Number: OC 11.4

    Force-Independent Cleavage of Talin by Calpain Promotes Platelet-mediated Fibrin Clot Contraction

    K.P.Y. Fong1, R.I. Litvinov1, O. Kim1, K. Molnar2, J.A. Wells2, J.W. Weisel1, W.F. DeGrado2, J.S. Bennett1

  • Abstract Number: PB0346

    Frequency and Clinical Significance of Different Types of Calreticulin (CALR) Mutations in Myeloproliferative Neoplasms (MPNs): A Cohort of Patients from Pakistan

    R. Ahmed1, M. Rashid2, U. Zaidi2, T. Shmasi2

  • Abstract Number: PB0457

    Frequency of Dosing and Presence of Endogenous VWF Influences FVIII Inhibitor Development

    M. Cormier1, K. Nesbitt1, P. Batty1, C. Hough1, D. Lillicrap1

  • Abstract Number: PB1171

    Frequency of Hereditary Thrombophilia in Venous Thromboembolic Disease

    K. Mendi1

  • Abstract Number: PB0885

    Frequent Platelet Dysfunction and Fibrinolysis in Patients with Intracerebral Hemorrhage

    P. Lindholm1, H. Kwaan2, I. Weiss2, A. Naidech3

  • Abstract Number: OC 16.1

    From Coagulation to Angiogenesis: Extra-coagulative Role of FVIII

    C. Olgasi1, A. Cucci1, C. Borsotti1, G. Walker1, I. Molineris2, F. Anselmi2, S. Assanelli1, C. Sgromo1, S. Oliviero2, A. Follenzi1

  • Abstract Number: PB0649

    From Stroke Treatment, through a Tongue Bite, until Intensive Care Unit: The Challenge of Antithrombotic Treatment in People with Haemophilia. A Case Report

    S. Teixeira1, I. Machado1, D. Gonçalves1, J.P. Silva2, S. Fernandes1, M. Lopes1, M. Carvalho1, D. Aranda1, C. Koch1

  • Abstract Number: LPB0109

    Full Automation of the Bethesda Assay

    T. Siegemund1, A. Siegemund1, H. Bönigk1

  • Abstract Number: PB0666

    Functional Transitory Anti-emicizumab Antibody Creating Bleeding Episodes

    F. Peyvandi1, S. Braham2, R. Gualtierotti1, S. Arcudi3, L. Schiavone2, C. Novembrino2, C. Valsecchi2

  • Abstract Number: PB0380

    FVIII Stability, the Limiting Factor in Chromogenic Fix Kits?

    A. Evenepoel1, C. Gavard1, S. Desmet1, V. Deneys1, M.-A. van Dievoet1

  • Abstract Number: PB0076

    FXI-independent Pathways of Contact Activation: Analysis of Activated Partial Thromboplastin Time (aPTT) Data Using Mathematical Modelling

    A. Rezvani-Sharif1, S. Rauth1, J. Arthur1, P. Niebl2, S. Dower1, C. Panousis1, I. Muir1

  • Abstract Number: LPB0110

    FXIIIa-mediated Fibrin γ-chain Crosslinks Are Critical for Fibrin Fiber Stiffness and Resistance to Rupture

    T. Feller1, C. Duval1, S.D.A. Connell2, R.A.S. Ariёns1

Jump to:  View All • a b c d e [f] g h i j k l m n o p q r s t u v w x y z
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley